{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T15:50:09Z","timestamp":1768924209522,"version":"3.49.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009991","name":"Department of Finance of Jilin Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009991","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The perioperative treatment model for locally advanced rectosigmoid junction cancer (LARSC) has not been finalized; whether this model should refer to the treatment model for rectal cancer remains controversial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We screened 10,188 patients with stage II\/III rectosigmoid junction adenocarcinoma who underwent surgery between 2004 and 2016 from the National Cancer Institute Surveillance, Epidemiology, and End Results database. Among them, 4,960 did not receive adjuvant chemotherapy, while 5,228 did receive adjuvant chemotherapy. Propensity score matching was used to balance the two groups for confounding factors, and the Kaplan-Meier method and log-rank test were used for survival analysis. Cox proportional hazards regression analysis was used to identify independent prognostic factors and build a predictive nomogram of survival for LARSC. X-tile software was used to divide the patients into three groups (low, medium, and high) according to their risk scores. 726 patients in our hospital were included for external validation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>LARSC patients did not show a benefit from neoadjuvant radiotherapy (P&amp;gt;0.05). After further excluding patients who received neoadjuvant radiotherapy, multivariate analysis found that age, grade, tumor size, T stage, and log odds of positive lymph nodes were independent prognostic factors for patients without adjuvant chemotherapy and were included in the nomogram. The C-index of the model was 0.690 (95% confidence interval: 0.668\u20130.712). We divided the patients into low, moderate, and high risk subgroups based on prediction scores of the nomogram. We found that adjuvant chemotherapy did not improve the prognosis of low risk patients, while moderate and high risk patients benefited from adjuvant therapy. External validation data found that moderate, and high risk patients also benefited from AT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Direct surgery plus adjuvant chemotherapy may be the best perioperative treatment for LARSC. Moreover, adjuvant chemotherapy is only recommended for moderate and high risk patients as it did not benefit low risk patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.772482","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T08:06:28Z","timestamp":1640333188000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["A Postsurgical Prognostic Nomogram for Locally Advanced Rectosigmoid Cancer to Assist in Patient Selection for Adjuvant Chemotherapy"],"prefix":"10.3389","volume":"11","author":[{"given":"Chao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shutao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3892\/or.2011.1343","article-title":"Stage II\/III Cancer of the Rectosigmoid Junction: An Independent Tumor Type","volume":"26","author":"Mukai","year":"2011","journal-title":"Oncol Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr473","article-title":"Short Course Chemotherapy Followed by Concomitant Chemoradiotherapy and Surgery in Locally Advanced Rectal Cancer: A Randomized Multicentric Phase II Study","volume":"23","author":"Mar\u00e9chal","year":"2012","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv223","article-title":"Chemoradiation, Surgery and Adjuvant Chemotherapy Versus Induction Chemotherapy Followed by Chemoradiation and Surgery: Long-Term Results of the Spanish GCR-3 Phase II Randomized Trial\u2020","volume":"26","author":"Fernandez-Martos","year":"2015","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw215","article-title":"PAN-EX: A Pooled Analysis of Two Trials of Neoadjuvant Chemotherapy Followed by Chemoradiotherapy in MRI-Defined, Locally Advanced Rectal Cancer","volume":"27","author":"Sclafani","year":"2016","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejca.2019.01.006","article-title":"Total Neoadjuvant Approach With FOLFOXIRI Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Locally Advanced Rectal Cancer: The TRUST Trial","volume":"110","author":"Masi","year":"2019","journal-title":"Eur J Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s1470-2045(20)30555-6","article-title":"Short-Course Radiotherapy Followed by Chemotherapy Before Total Mesorectal Excision (TME) Versus Preoperative Chemoradiotherapy, TME, and Optional Adjuvant Chemotherapy in Locally Advanced Rectal Cancer (RAPIDO): A Randomised, Open-Label, Phase 3 Trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.6486","article-title":"Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial","volume":"6","author":"Petrelli","year":"2020","journal-title":"JAMA Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01330","article-title":"Duration of Adjuvant Doublet Chemotherapy (3 or 6 Months) in Patients With High-Risk Stage II Colorectal Cancer","volume":"39","author":"Iveson","year":"2021","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.22.0467","article-title":"Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03","volume":"27","author":"Roh","year":"2009","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.148.3.6878708","article-title":"A Method of Comparing the Areas Under Receiver Operating Characteristic Curves Derived From the Same Cases","volume":"148","author":"Hanley","year":"1983","journal-title":"Radiology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.eururo.2018.08.038","article-title":"Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators","volume":"74","author":"Van Calster","year":"2018","journal-title":"Eur Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-04-0713","article-title":"X-Tile: A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization","volume":"10","author":"Camp","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2020.06.039","article-title":"Comparison of the Sigmoid Take-Off With Other Definitions of the Rectosigmoid Junction: A Retrospective Comparative Cohort Analysis","volume":"80","author":"Li","year":"2020","journal-title":"Int J Surg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0032","article-title":"NCCN Guidelines Insights: Rectal Cancer, Version 6.2020","volume":"18","author":"Benson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.40.1836","article-title":"Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO\/ARO\/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years","volume":"30","author":"Sauer","year":"2012","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)71199-4","article-title":"Adjuvant Chemotherapy After Preoperative (Chemo)Radiotherapy and Surgery for Patients With Rectal Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data","volume":"16","author":"Breugom","year":"2015","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/annonc\/mdu560","article-title":"Adjuvant Chemotherapy for Rectal Cancer Patients Treated With Preoperative (Chemo)Radiotherapy and Total Mesorectal Excision: A Dutch Colorectal Cancer Group (DCCG) Randomized Phase III Trial","volume":"26","author":"Breugom","year":"2015","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu147","article-title":"Chronicle: Results of a Randomised Phase III Trial in Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation Randomising Postoperative Adjuvant Capecitabine Plus Oxaliplatin (XELOX) Versus Control","volume":"25","author":"Glynne-Jones","year":"2014","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(13)70599-0","article-title":"Fluorouracil-Based Adjuvant Chemotherapy After Preoperative Chemoradiotherapy in Rectal Cancer: Long-Term Results of the EORTC 22921 Randomised Study","volume":"15","author":"Bosset","year":"2014","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2014.10.006","article-title":"No Benefit of Adjuvant Fluorouracil Leucovorin Chemotherapy After Neoadjuvant Chemoradiotherapy in Locally Advanced Cancer of the Rectum (LARC): Long Term Results of a Randomized Trial (I-CNR-Rt)","volume":"113","author":"Sainato","year":"2014","journal-title":"Radiother Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(11)70097-3","article-title":"Preoperative Radiotherapy Combined With Total Mesorectal Excision for Resectable Rectal Cancer: 12-Year Follow-Up of the Multicentre, Randomised Controlled TME Trial","volume":"12","author":"van Gijn","year":"2011","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2013.10.024","article-title":"EURECCA Consensus Conference Highlights About Rectal Cancer Clinical Management: The Radiation Oncologist\u2019s Expert Review","volume":"110","author":"Valentini","year":"2014","journal-title":"Radiother Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2016.12.019","article-title":"Changes in Nationwide Use of Preoperative Radiotherapy for Rectal Cancer After Revision of the National Colorectal Cancer Guideline","volume":"43","author":"Gietelink","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000003649","article-title":"Neoadjuvant Radiotherapy Versus Surgery Alone for Stage II\/III Mid-Low Rectal Cancer With or Without High-Risk Factors: A Prospective Multicenter Stratified Randomized Trial","volume":"272","author":"Deng","year":"2020","journal-title":"Ann Surg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/codi.14994","article-title":"Postoperative Chemotherapy Improves Survival in Patients With Resected High-Risk Stage II Colorectal Cancer: Results of a Systematic Review and Meta-Analysis","volume":"22","author":"Simillis","year":"2020","journal-title":"Colorectal Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-004-0738-1","article-title":"Are Survival Rates Different for Young and Older Patients With Rectal Cancer","volume":"47","author":"O\u2019Connell","year":"2004","journal-title":"Dis Colon Rectum"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.12033","article-title":"Aspirin Use After Diagnosis Improves Survival in Older Adults With Colon Cancer: A Retrospective Cohort Study","volume":"60","author":"Reimers","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa114","article-title":"Effect of Aspirin on Cancer Incidence and Mortality in Older Adults","volume":"113","author":"McNeil","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-004-0723-8","article-title":"Free Colorectal Cancer Cells on the Peritoneal Surface: Correlation With Pathologic Variables and Survival","volume":"47","author":"Baskaranathan","year":"2004","journal-title":"Dis Colon Rectum"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.7150\/jca.28917","article-title":"Survival Benefit of Adjuvant Chemotherapy for Patients With Poorly Differentiated Stage IIA Colon Cancer","volume":"10","author":"Liu","year":"2019","journal-title":"J Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2013.2136","article-title":"A Novel Risk-Adjusted Nomogram for Rectal Cancer Surgery Outcomes","volume":"148","author":"Russell","year":"2013","journal-title":"JAMA Surg"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2014.12.008","article-title":"Tumor Size Predicts Long-Term Survival in Colon Cancer: An Analysis of the National Cancer Data Base","volume":"209","author":"Saha","year":"2015","journal-title":"Am J Surg"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.23.9194","article-title":"Revised Tumor and Node Categorization for Rectal Cancer Based on Surveillance, Epidemiology, and End Results and Rectal Pooled Analysis Outcomes","volume":"28","author":"Gunderson","year":"2010","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/codi.12702","article-title":"The Prognostic Impact of the Log Odds of Positive Lymph Nodes in Colon Cancer","volume":"16","author":"Arslan","year":"2014","journal-title":"Colorectal Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.06.8866","article-title":"Increasing Negative Lymph Node Count Is Independently Associated With Improved Long-Term Survival in Stage IIIB and IIIC Colon Cancer","volume":"24","author":"Johnson","year":"2006","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.661040","article-title":"A Novel Prognostic Model and Practical Nomogram for Predicting the Outcomes of Colorectal Cancer: Based on Tumor Biomarkers and Log Odds of Positive Lymph Node Scheme","volume":"11","author":"Zhu","year":"2021","journal-title":"Front Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.7150\/jca.38180","article-title":"Prognosis of Colorectal Cancer Patients Is Associated With the Novel Log Odds of Positive Lymph Nodes Scheme: Derivation and External Validation","volume":"11","author":"Zhang","year":"2020","journal-title":"J Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30053","article-title":"Adjuvant Chemotherapy Is Not Associated With Improved Survival for All High-Risk Factors in Stage II Colon Cancer","volume":"139","author":"Verhoeff","year":"2016","journal-title":"Int J Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.772482\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T08:06:33Z","timestamp":1640333193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.772482\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,24]]},"references-count":40,"alternative-id":["10.3389\/fonc.2021.772482"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.772482","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,24]]},"article-number":"772482"}}